|  |  |  |  |
| --- | --- | --- | --- |
|  | Time-point 12-16w post 2nd vaccine | Time-point 2~6m post 2nd vaccine | Time-point 31-16w post 3rd vaccine |
| Participant | Mean IgG (AU/ml)% positive | Mean IFNγ(pg/ml)% positive | Mean IgG (AU/ml)% positive | Mean IFNγ(pg/ml)% positive | Mean IgG (AU/ml)% positive | Mean IFNγ(pg/ml)% positive |
| Untreated | 2447 (N=2)100% | 322100% | 275 (N=1)100% | 168100% | 5577 (N=2)100% | 208100% |
| Cladribine |  |  | 296.3 (N=1)100% | 54100% |  |  |
| Dimethyl Fumarate | 18369 (N=2)100% | 6309 100% |  |  | 3243(N=1)100% | 52100% |
| Fingolimod  | 94 (N=4)**50%** | 46**25%** |  |  | 59.5 (N=4)**25%** | 0**0%** |
| Ponesimod | 186 (N=1)100% | 249100% |  |  |  |  |
| Siponimod | 301 (N=1)100% | 35100% |  |  |  |  |
| Glatiramer Acetate | 3357 (N=1)100% | 81100% |  |  |  |  |
| Interferon beta (Rebif) | 1082 (N=1)100% | 121100% |  |  |  |  |
| Methotrexate | 1258 (N=1) 100% | 117 100% |  |  |  |  |
| Natalizumab | 19571 (N=4)100% | 1426100% |  |  |  |  |
| Ocrelizumab | 368 (N=4)**25%** | 882100% | 18.9 (N=1)**0%** | 758100% | 357 (N=7)**57%** | 837**86%** |
| Ofatumumab | 2989 (N=2)100% | 170100% |  |  | 10230.4 (N=1)100% | 347100% |
| Teriflunomide |  |  |  |  | 568 (N=1)100% | 0**0%** |
| Healthy | 3561.3 (N=6)100% | 401100% |  |  | 4429(N=2)100% | 87.5100% |

**Supplemental Table 3 Serological and IFNγ-T cell immune response**